We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-6.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$647M
AUM Growth
-$83.7M
Cap. Flow
-$10M
Cap. Flow %
-1.55%
Top 10 Hldgs %
49.16%
Holding
110
New
21
Increased
23
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$30.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$24M
3
NVO
Novo Nordisk
NVO
+$22.8M
4
PTCT icon
PTC Therapeutics
PTCT
+$13.5M
5
GILD icon
Gilead Sciences
GILD
+$13.4M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$31.8M
2
GSK icon
GSK
GSK
+$20M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$19.3M
4
VRNT
Verint Systems
VRNT
+$15.6M
5
BLUE
bluebird bio
BLUE
+$9.54M

Sector Composition

Rank Sector Weight
1 Healthcare 74.15%
2 Technology 11.83%
3 Industrials 2.25%
4 Consumer Discretionary 1.19%
5 Communication Services 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$133B
$56.3M 8.69%
1,109,900
+180,000
+19% +$8.46M
JNJ icon
2
Johnson & Johnson
JNJ
$618B
$51.8M 7.99%
400,000
– –
MRK icon
3
Merck
MRK
$322B
$39.6M 6.11%
492,560
+18,864
+4% +$1.51M
SNY icon
4
Sanofi
SNY
$103B
$32.4M 5.01%
+700,000
New +$30.2M
GILD icon
5
CALL
Gilead Sciences
GILD
$162B
$31.7M 4.9%
+500,000
New +$32.7M
CELG
6
DELISTED
Celgene Corp
CELG
$24.8M 3.84%
250,000
– –
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$23.5M 3.63%
2,930,320
+420,000
+17% +$4.56M
NVO
8
Novo Nordisk
NVO
$208B
$23.3M 3.59%
+900,000
New +$22.8M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.57B
$18.7M 2.89%
248,038
+203,038
+451% +$24M
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$16.2M 2.51%
165,713
-171,087
-51% -$19.3M
ARQL
11
DELISTED
Arqule Inc
ARQL
$14.9M 2.31%
2,082,643
+300,000
+17% +$2.82M
GILD icon
12
Gilead Sciences
GILD
$162B
$13M 2.01%
+205,000
New +$13.4M
TEVA icon
13
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$10.7M 1.65%
1,550,000
-500,000
-24% -$3.83M
PTCT icon
14
PTC Therapeutics
PTCT
$5.64B
$10.5M 1.62%
+310,000
New +$13.5M
GWPH
15
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.51M 1.32%
+74,000
New +$11.2M
MLNX
16
DELISTED
Mellanox Technologies, Ltd.
MLNX
$8.43M 1.3%
76,875
+53,658
+231% +$5.92M
NICE icon
17
Nice
NICE
$5.79B
$8.22M 1.27%
57,193
+55,422
+3,129% +$8.28M
DRNA
18
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$8.11M 1.25%
565,000
+250,358
+80% +$3.58M
URGN icon
19
UroGen Pharma
URGN
$1.86B
$8M 1.24%
335,817
+27,440
+9% +$897K
RCKT icon
20
Rocket Pharmaceuticals
RCKT
$340M
$7.69M 1.19%
660,000
+350,000
+113% +$4.34M
CSTE icon
21
Caesarstone
CSTE
$72.3M
$7.67M 1.18%
461,509
-76,807
-14% -$1.17M
MSFT icon
22
Microsoft
MSFT
$3.45T
$7.47M 1.15%
53,741
– –
STOK icon
23
Stoke Therapeutics
STOK
$1.8B
$7.38M 1.14%
346,380
-4,564
-1% -$127K
ASND icon
24
Ascendis Pharma A/S
ASND
$16B
$7.11M 1.1%
73,773
– –
QURE icon
25
uniQure
QURE
$3.03B
$6.99M 1.08%
177,500
+117,351
+195% +$6.77M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sphera Funds Management held 110 positions worth $647M, down 11% from $731M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sphera Funds Management's Q3 2019 filing shows 21 new, 23 increased, 14 reduced and 30 closed positions. Its largest new stake was Sanofi: 700,000 shares worth $32.4M. The largest sale was AstraZeneca, an estimated $31.8M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 70% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q3 2019 buy was Sanofi: 700,000 shares worth $32.4M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q3 2019, an estimated $24M increase.
  • Sphera Funds Management's biggest Q3 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $19.3M.
  • Sphera Funds Management fully exited AstraZeneca in Q3 2019, selling an estimated $31.8M.
  • Sphera Funds Management's ten largest holdings make up 49% of its $647M portfolio in Q3 2019.
  • Sphera Funds Management opened 21 new positions and closed 30 in Q3 2019.
  • Sphera Funds Management's portfolio value fell 11% quarter-over-quarter to $647M.

Based on Sphera Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.